Gen9, Amyris Announce Supply Agreement

Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.’s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world’s leading brands. The collaboration is part of Gen9’s MAP program, fueled by the BioFab® DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.

“A fast, reliable source of high-quality synthetic DNA constructs is an essential component of our microbial engineering platform for the production of high value molecules. Gen9 consistently provides that for us,” said Joel Cherry, Amyris President of Research and Development. “With the DNA synthesis throughput and economics that Gen9 offers, we are able to engineer and test new strains more cost effectively, using them to rapidly identify the highest-performing microbes and allowing us to bring sustainable products to market more quickly.”

“Amyris is developing a wide range of innovative products with their platform, from plant-derived cosmetic ingredients, to renewable lubricants, to novel biopharmaceuticals,” said Kevin Munnelly, President and CEO of Gen9. “We are excited that Gen9 DNA will be utilized to develop products that will solve some of the most important global challenges we face today.”